No photo of Mark Agulnik

View Scopus Profile

Mark Agulnik

  • 2729 Citations
20012023
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Certifications and Licenses

Hematology
Medical Oncology

Training Experience

2001Residency, Dalhousie University, Canada
2004Fellowship, Univ. of Illinois Hospital

Education/Academic qualification

MD, McGill University

… → 1998

Research interests

  • Head and Neck Cancer
  • Salivary Gland Tumors
  • Sarcomas
  • Thyroid Cancer

Fingerprint Dive into the research topics where Mark Agulnik is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 9 Similar Profiles
Sarcoma Medicine & Life Sciences
Head and Neck Neoplasms Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Epidermal Growth Factor Receptor Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Protein-Tyrosine Kinases Medicine & Life Sciences
Gastrointestinal Stromal Tumors Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2005 2023

Prot #AL3818-US-004: A Phase III Study of AL3818 (Anlotinib) Hydrochloride Monotherapy in Subjects with Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma

Agulnik, M.

Advenchen Laboratories, LLC

9/20/19 → 9/20/22

Project: Research project

Prot #GTI-4419-301: ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419) – Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Headand Neck Cancer

Agulnik, M.

Clinical Assistance Programs, LLC, Galera Therapeutics, Inc.

9/19/19 → 9/19/22

Project: Research project

Prot #BLU-285-EAP-01: Early Access Program (EAP) for Avapritinib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Agulnik, M.

WE Pharma, Inc, Blueprint Medicines Corporation

7/23/19 → 7/23/21

Project: Research project

Prot #DCC-2618-03-002: A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib

Agulnik, M.

Deciphera Pharmaceuticals, LLC

4/22/19 → 4/22/22

Project: Research project

Prot #ISA101b-HN-01-17: A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study of Cemiplimab Versus the Combination of Cemiplimab With ISA101b in the Treatment of Subjects With HPV16-Positive Platin-Resistant Oropharyngeal Cancer (OPC)

Agulnik, M.

Syneos Health, Inc., ISA Therapeutics B.V.

4/22/19 → 4/22/22

Project: Research project

Research Output 2001 2019

  • 2729 Citations
  • 52 Article
  • 26 Review article
  • 3 Comment/debate
  • 1 Short survey

A phase II clinical study of 13-deoxy, 5-iminodoxorubicin (GPX-150) with metastatic and unresectable soft tissue sarcoma

Van Tine, B. A., Agulnik, M., Olson, R. D., Walsh, G. M., Klausner, A., Frank, N. E., Talley, T. T. & Milhem, M. M., Jun 1 2019, In : Cancer medicine. 8, 6, p. 2994-3003 10 p.

Research output: Contribution to journal › Article

Open Access
Sarcoma
Doxorubicin
Type II DNA Topoisomerase
Survival Rate
Leukopenia

Ectopic hamartomatous thymoma in an immunocompromised male

Waters, D., Obeidin, F., Alexiev, B. A., Musunuri, S. R., Peabody, T. D., Agulnik, M. & Yeldandi, A. V., Sep 1 2019, In : Pathology Research and Practice. 215, 9, 152497.

Research output: Contribution to journal › Article

Thymoma
Keratins
Salivary Glands
Breast
Synovial Sarcoma
1 Citation (Scopus)

Piloting a financial counseling intervention for patients with cancer receiving chemotherapy

Kircher, S. M., Yarber, J., Rutsohn, J., Guevara, Y., Lyleroehr, M., Jackson, H. A., Walradt, J., Desai, B., Mulcahy, M. F., Kalyan, A., Benson III, A. B., Agulnik, M., Mohindra, N. A., DeSouza, J. & Garcia, S. F., Mar 1 2019, In : Journal of oncology practice. 15, 3, p. E202-E210

Research output: Contribution to journal › Article

Counseling
Drug Therapy
Neoplasms
Costs and Cost Analysis
Workflow
2 Citations (Scopus)

Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma

Davis, L. E., Bolejack, V., Ryan, C. W., Ganjoo, K. N., Loggers, E. T., Chawla, S., Agulnik, M., Livingston, M. B., Reed, D., Keedy, V., Rushing, D., Okuno, S., Reinke, D. K., Riedel, R. F., Attia, S., Mascarenhas, L. & Maki, R. G., Jan 1 2019, In : Journal of Clinical Oncology. 37, 16, p. 1424-1431 8 p.

Research output: Contribution to journal › Article

Osteosarcoma
Disease-Free Survival
Placebos
Sarcoma
Clinical Trials Data Monitoring Committees
39 Citations (Scopus)

Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: An international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742)

Ma, B. B. Y., Lim, W. T., Goh, B. C., Hui, E. P., Lo, K. W., Pettinger, A., Foster, N. R., Riess, J. W., Agulnik, M., Chang, A. Y. C., Chopra, A., Kish, J. A., Chung, C. H., Adkins, D. R., Cullen, K. J., Gitlitz, B. J., Lim, D. W., To, K. F., Chan, K. C. A., Lo, Y. M. D. & 5 others, King, A. D., Erlichman, C., Yin, J., Costello, B. A. & Chan, A. T. C., Jan 1 2018, In : Journal of Clinical Oncology. 36, 14, p. 1412-1418 7 p.

Research output: Contribution to journal › Article

Multicenter Studies
Survival Rate
Ligands
Disease-Free Survival
Biomarkers